Renalys Pharma, a Tokyo, Japan-based late-stage clinical biopharmaceutical company, raised a ¥6.0Bn in Series A funding.
The round was led by Catalys Pacific and SR One, with participation from JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank Co., Ltd., Japan Co-Invest IV Limited Partnership, NVCC NO.9 Investment Limited Partnership.
Led by CEO BT Slingsby, Renalys Pharma, is a privately held late-stage clinical biopharmaceutical company committed to the development of multiple innovative therapeutics targeting unmet needs in the management of renal disease for Japanese and Asian patients. It aims to address the problem of “drug loss” by catalyzing access to new treatments for kidney disease patients in Japan and other Asian regions
The company intends to use the funds to complete its Phase III clinical trial for sparsentan, a promising treatment for IgA nephropathy, in Japan. IgA nephropathy is a prevalent kidney disease in Japan and throughout Asia.
Renalys Pharma obtained the rights to sparsentan through a licensing agreement with Travere Therapeutics, Inc. In April 2024, the company submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and plans to initiate an open-label registrational study in Q2 2024, with anticipated results from the urine protein/creatinine ratio endpoint in the second half of 2025. This Phase III registration study will bring Renalys Pharma closer to providing a much-needed treatment option for patients living with IgA nephropathy across the region.
FinSMEs
18/07/2024